Abbott India Ltd, a Mumbai-based pharmaceutical company, is planning to launch around 100 products over the next five years, as part of its effort to consolidate the company’s existing therapy areas and grow over-the-counter portfolio.
“Abbott plans to launch around 100 products over the next five years. Our focus remains on growing existing therapy areas such as gastroenterology, metabolics, vaccines, central nervous system and women’s health,” said the company’s Managing Director, Ambati Venu.
“The company is also looking at strengthening its over-the-counter portfolio with a wider range of product formats,” he added.
“In total, our pharmaceutical business covers 90 percent of therapies in India so our goals are to increase the depth and breadth of the medicines we offer in these areas, ensure broader reach to people in India and continue to launch improved medicines that make it better or easier for people to get healthy,” said the managing director.
Abbott India, the drug major, is listed on the BSE and currently offers over 110 brands and covers multiple therapeutic areas such as women’s health, gastroenterology, neurology, thyroid, pain management, general care, vitamins and vaccines.